Skip to main content
Premium Trial:

Request an Annual Quote

OSU Team Develops New Approach for Personalized Warfarin Treatment

Premium

A team led by Haifeng Wu, an associate professor of pathology and internal medicine at Ohio State University, recently demonstrated a new rapid multiplexed genotyping method that promises to bring a personalized approach to warfarin therapy. Despite its effectiveness, the widely prescribed anti-coagulant drug has many contraindications with common medications, as well as with chemicals present in some foods, so a physician's ability to choose the correct dosage is crucial — especially as potential side effects include bleeding and clot development.

Wu's group used surface-enhanced laser desorption and ionization time-of-flight mass spec to determine three warfarin-related SNPs in less than five hours, with a high rate of accuracy.

SELDI-TOF is a flavor of mass spec that, when combined with chip technology, facilitates efficient enrichment of a DNA analyte prior to the detection process, thereby permitting investigators to more effectively identify SNPs of possible clinical significance. "In comparison to other methods for SNP analysis, SELDI-TOF provides similar — if not better — analytical performance such as test turnaround time, test precision, and cost effectiveness," Wu says. "Enabling the on-site detection of SNPs influencing warfarin therapy in the hospital setting would help clinicians to get same-day results so that they can administer initial doses to their patients correctly."

Wu's group is now working -closely with the Center for Personalized Health Care at Ohio State to apply their SELDI-TOF platform to develop protocols to pin down other medically significant SNPs that affect the efficacy of drug therapies. Areas of interest include SNPs that influence the effect of the anti-platelet drug Plavix and the breast cancer drug tamoxifen. "We have demonstrated through research a proof of principle for a plausible application of this unique method," he says. "The next step is to build a business-academic partnerships to further refine SELDI-TOF technology and eventually bring about a broader application of this approach to benefit more patients."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.